ADMA Biologics Competitors and Similar CompaniesClear all
ADMA Biologics's competitors and similar companies include CorMedix, Autolus, Longboard Pharmaceuticals and Array BioPharma.
 ADMA Biologics ADMA Biologics develops plasma-based biologics for the treatment and prevention of certain infectious diseases. |  CorMedix CorMedix is a pharmaceutical company that seeks to in-license, develop and commercialize therapeutic products for the treatment of cardiac and kidney disease. |  Autolus Autolus Therapeutics is a private biopharmaceutical company, focused on the development and commercialization of engineered T-cell immunotherapy products. |  Longboard Pharmaceuticals Longboard Pharmaceuticals, Inc. (Longboard) is a biopharmaceutical company focused on developing transformative medicines for neurological diseases. |  Array BioPharma Array BioPharma is focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. | |
Founding Date | Founding Date 2004 | Founding Date 2006 | Founding Date 2014 | Founding Date 2020 | Founding Date 1998 |
Type | Type Public | Type Public | Type Public | Type Public | Type Subsidiary |
Tags | |||||
Locations | Locations Ramsey, US HQ Boca Raton, US | Locations Berkeley Heights, US HQ | Locations London, GB HQ London, GB | Locations San Diego, US HQ San Diego, US | Locations Boulder, US HQ Chicago, US Detroit, US Houston, US Miami, US New York, US Phoenix, US |
Employees | Employees 313 | Employees 3036% increase | Employees 647 | Employees 5056% increase | Employees 110 |
Valuation ($) | Valuation ($) 3.9 b | Valuation ($) 749.2 m | Valuation ($) 1.2 b | Valuation ($) 2.3 b | Valuation ($) N/A |
Financial | |||||
Revenue (est.) | Revenue (est.) $510.2m (FY, 2025) | Revenue (est.) $311.7m (FY, 2025) | Revenue (est.) $75.4m (FY, 2025) | Revenue (est.) N/A | Revenue (est.) $173.8m (FY, 2018) |
Cost of goods | Cost of goods $217.4m (FY, 2025) | Cost of goods $22.1m (FY, 2025) | Cost of goods $86.6m (FY, 2025) | Cost of goods N/A | Cost of goods $59.4m (FY, 2018) |
Gross profit | Gross profit $292.8m (FY, 2025) | Gross profit $275.7m (FY, 2025) | Gross profit ($10.7m) (FY, 2025) | Gross profit N/A | Gross profit $114.4m (FY, 2018) |
Net income | Net income $146.9m (FY, 2025) | Net income $163.1m (FY, 2025) | Net income ($287.5m) (FY, 2025) | Net income ($54.4m) (FY, 2023) | Net income ($147.7m) (FY, 2018) |
Funding | |||||
Total funding raised | Total funding raised $ 20m | Total funding raised $ 11.5m | Total funding raised $ 281.7m | Total funding raised $ 56m | Total funding raised N/A |
For sources of this data, please see the company profile
View Company Profiles
CorMedix
HQ
Berkeley Heights, US
Employees
30↑ 36% increase
CorMedix is a pharmaceutical company that seeks to in-license, develop and commercialize therapeutic products for the treatment of cardiac and kidney disease.
View companyAutolus
HQ
London, GB
Employees
647
Autolus Therapeutics is a private biopharmaceutical company, focused on the development and commercialization of engineered T-cell immunotherapy products.
View companyLongboard Pharmaceuticals
HQ
San Diego, US
Employees
50
Longboard Pharmaceuticals, Inc. (Longboard) is a biopharmaceutical company focused on developing transformative medicines for neurological diseases.
View companyArray BioPharma
HQ
Boulder, US
Array BioPharma is focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer.
View company